Publication: Racial differences in neuromyelitis optica spectrum disorder
Issued Date
2018-11-27
Resource Type
ISSN
1526632X
00283878
00283878
Other identifier(s)
2-s2.0-85057148184
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neurology. Vol.91, No.22 (2018), E2089-E2099
Suggested Citation
Su Hyun Kim, Maureen A. Mealy, Michael Levy, Felix Schmidt, Klemens Ruprecht, Friedemann Paul, Marius Ringelstein, Orhan Aktas, Hans Peter Hartung, Nasrin Asgari, Jessica Li Tsz-Ching, Sasitorn Siritho, Naraporn Prayoonwiwat, Hyun June Shin, Jae Won Hyun, Mira Han, Maria Isabel Leite, Jacqueline Palace, Ho Jin Kim Racial differences in neuromyelitis optica spectrum disorder. Neurology. Vol.91, No.22 (2018), E2089-E2099. doi:10.1212/WNL.0000000000006574 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46180
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Racial differences in neuromyelitis optica spectrum disorder
Author(s)
Other Contributor(s)
National Cancer Center, Gyeonggi
University of Oxford
Charité – Universitätsmedizin Berlin
Heinrich Heine Universität
Max Delbruck Center for Molecular Medicine
Syddansk Universitet
Queen Elizabeth Hospital Hong Kong
Faculty of Medicine, Siriraj Hospital, Mahidol University
The Johns Hopkins School of Medicine
Humboldt-Universität zu Berlin
Biometric Research Branch
University of Oxford
Charité – Universitätsmedizin Berlin
Heinrich Heine Universität
Max Delbruck Center for Molecular Medicine
Syddansk Universitet
Queen Elizabeth Hospital Hong Kong
Faculty of Medicine, Siriraj Hospital, Mahidol University
The Johns Hopkins School of Medicine
Humboldt-Universität zu Berlin
Biometric Research Branch
Abstract
© 2018 American Academy of Neurology. Objective We aimed to evaluate racial differences in the clinical features of neuromyelitis optica spectrum disorder. Methods This retrospective review included 603 patients (304 Asian, 207 Caucasian, and 92 Afro- American/Afro-European), who were seropositive for anti-aquaporin-4 antibody, from 6 centers in Denmark, Germany, South Korea, United Kingdom, United States, and Thailand. Results Median disease duration at last follow-up was 8 years (range 0.3-38.4 years). Asian and Afro- American/Afro-European patients had a younger onset age than Caucasian patients (mean 36, 33, and 44 years, respectively; p < 0.001). During the disease course, Caucasian patients (23%) had a lower incidence of brain/brainstem involvement than Asian (42%) and Afro-American/ Afro-European patients (38%) (p < 0.001). Severe attacks (visual acuity ≤0.1 in at least one eye or Expanded Disability Status Scale score ≥6.0 at nadir) at onset occurred more frequently in Afro-American/Afro-European (58%) than in Asian (46%) and Caucasian (38%) patients (p = 0.005). In the multivariable analysis, older age at onset, higher number of attacks before and after immunosuppressive treatment, but not race, were independent predictors of severe motor disabilities at last follow-up. Conclusion A review of a large international cohort revealed that race affected the clinical phenotype, age at onset, and severity of attacks, but the overall outcome was most dependent on early and effective immunosuppressive treatment.
